


safety notices.




Use of excluded high cost drugs (HCD) <u>with methotrexate</u> in the treatment of Severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAs 195, 225, 247, 375, 415, 466, 480, 485, 665, 676 & local agreement







Use of excluded high cost drugs (HCD) Monotherapy in the treatment of Severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAS 195, 375, 415, 466, 480, 485, 665, 676 and local agreement



Refer to individual <u>SPC</u>'s for full prescribing information including dose restrictions, adverse drug reactions, contraindications and cautions; and to <u>Drug Safety Updates</u> for latest drug safety notices.

s/c), sulfasalazine, hydroxychloroquine, penicillamine, azathioprine, leflunomide





Version	1.1
Developed by	Pharmacy and medicines optimisation team Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	December 2022
Review Date	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available
Superseded version	Pathway for use of biologics with Methotrexate for Rheumatoid Arthritis. WEMOPB, August 2021 Pathway for use of biologic monotherapy for Rheumatoid Arthritis. WEMOPB, May 2021 Use of excluded HCDs with methotrexate in the treatment of severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAs 195, 225, 247, 375, 415, 466, 480, 485, 665, 676 & local agreement Use of excluded HCD Monotherapy in the treatment of severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAs 195, 375, 415, 466, 480, 485, 665, 676 and local agreement Both HMMC, November 2021 1.0 Use of excluded HCDs with methotrexate in the treatment of severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAs 195, 225, 247, 375, 415, 466, 480, 485, 665, 676 & local agreement Use of excluded HCD Monotherapy in the treatment of severe Rheumatoid Arthritis in Adults Treatment pathway in line with NICE TAs 195, 375, 415, 466, 480, 485, 665, 676 and local agreement Both APC, December 2022. Updated to reflect introduction of tocilizumab biosimilar and box to note future updates as prices change or biosimilar medicines become available.

NICE recommends if patients and their clinicians consider a medicine to be one of a range of suitable treatments, the least expensive treatment should be chosen, taking into account administration costs, dosage, price per dose and commercial arrangements. Therefore, in line with this recommendation and HWE APC agreed principles the order of preference of treatments within this pathway will be updated accordingly as prices change or biosimilar medicines become available.